Fiber strand and implantable supporting body having a fiber strand

• US 7,997,054 B2
• Filed: 06/09/2009
• Issued: 08/16/2011
• Est. Priority Date: 06/25/2008
• Status: Expired due to Fees

• Current Assignee: Biotronik AG (Biotronik SE & Company KG)
• Original Assignee: Biotronik VI Patent AG (Biotronik SE & Company KG)
• Inventors: Müller, Heinz, Bertsch, Torben
• Primary Examiner(s): Hurley; Shaun R
• Application Number:
  US12/480,683
• Publication Number:
  US 20090320435A1
• Time in Patent Office: 798 Days
• Field of Search: 572/57, 572/58
• US Class Current: 57/257
• CPC Class Codes: A61F 2/82 Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95; for closing wounds, or holding wounds closed A61B17/04 - A61B17/115; dilators A61M29/00
• CPC Class Codes: A61F 2210/0004 bioabsorbable
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: Y10T 428/2913 Rod, strand, filament or fiber

Abstract

The invention relates to a fiber strand (10) for an implantable supporting body (100) comprising at least two individual fibers (12). The at least two individual fibers (12) are each shorter in their longitudinal extent than the longitudinal extent (14) of the fiber strand, and in their transverse extent they are each thinner than the transverse extent (16) of the fiber strand.

Claims

1. A fiber body for an implantable supporting body comprising a plurality of cords (30) forming a sheath (36) that surrounds a core, wherein each cord (30) comprises a plurality of fiber strands (10), wherein each of the plurality of fiber strands comprises at least two individual fibers (12), characterized in that the at least two individual fibers (12) are each shorter in their longitudinal extent than the longitudinal extent (14) of the fiber strand and their transverse extent is thinner than the transverse extent (16) of the fiber strand.

2. The fiber strand according to claim 1, characterized in that,

a ratio of longitudinal extent of the individual fiber to the longitudinal extent (14) of the fiber strand is between a range of 2:

1 and 200,000;

1 or between a range of 10;

1 and 100,000;

1;

or

a ratio of individual fiber transverse extent to fiber strand transverse extend (16) is in a range between 2;

1 and 200,000;

1 or between 10;

1 and 100,000;

1.

3. The fiber strand according to claim 1, characterized in that,

at least one of the individual fibers (12) comprises a material of comprising carbon or a carbonaceous material;

or

at least one of the individual fibers (12) is made of a metallic material comprising at least one member selected from the group consisting of Fe, Cr, Co, Wo, Ni, Zn, Mg, Ti, Mn, Pt, Mo, Ta, Ir, Ag, and Au in crystalline, partially crystalline or amorphous structure;

or

at least one of the individual fibers (12) is made of at least one ceramic material comprising at least one member selected from the group consisting of Br, I, Zr, Al, N, F, Si, Ga, Ti, O, Au and Ag in crystalline, partially crystalline or amorphous structure.

4. The fiber strand according to claim 1, characterized in that the individual fibers (12) are treated with a matrix material (22).

5. The fiber strand according to claim 4, characterized in that the matrix material (22) comprises at least one substance selected from the group consisting of a lipid regulator, an immunosuppressant, a vasodilator, a calcium channel blocker, a calcineurin inhibitor, an antiphlogistics, an anti-inflammatory, an anti-allergic, an oligonucleotide, an estrogen, an endothelializing agent, a steroid, a protein or peptide, a proliferation inhibitor, an analgesic, an antirheumatic, paclitaxel, rapamycin,

optionally characterized in that the matrix material is loaded with a member selected from the group consisting of a polymer, a nonresorbable/permanent polymer, polytetrafluoroethylene, a poly-amide, a polyether imide, polyether sulfone, poly(iso)butylene, polyvinyl chloride, polyvinyl fluoride, polyvinyl alcohol, polyurethane, polybutylene terephthalate, a silicone, polyphosphazene, or a polymer foam,

optionally further characterized in that the polymer is loaded with a member selected from the group consisting of a resorbable/bioresorbable/degradable polymer, copolymer or a blend, a triblock copolymer, a polysaccharide, polyhydroxy valerate, ethylvinyl acetate, polyethylene oxide, polyphos-phorylcholine, fibrin, albumin, and polyhydroxybutyric acid.

6. The fiber strand according to claim 5, characterized in that the lipid regulator is a fibrate;

the vasodilator is a sartan;

the calcineurin inhibitor is tacrolimus;

the antiphlogistic is cortisone or diclofenac;

the anti-inflammatory is imidazole;

the oligonucleotide is dODN;

the estrogen is genistein;

the endothelializing agent is fibrin;

the nonresorbable/permanent polymer is selected from the group consisting of polypropylene, polyethylene, polyvinyl chloride, and polyacrylate, wherein the polyacrylate is selected from the group consisting of polyethyl or polymethyl acrylate, polymethyl methacrylate, polymethyl-co-ethyl-acrylate, and ethylene/ethyl acrylate;

the polytetrafluoroethylene is ethylene/chlorotrifluoroethylene copolymer;

the poly-amide is selected from the group consisting of polyamide imide, PA-11, PA-12, PA46, or PA-66;

the polymer foams is from a carbonate or styrene;

the polymer loaded with resorbable/bioresorbable/degradable polymer is selected from the group consisting of polydioxanone, polyglycolide, polycaprolactone, polylactide, poly-L-lactide, poly-D,L-lactide;

the copolymer or blend is selected from the group consisting of poly(L-lactide-co-glycolide), poly(D,L-lactide-co-glycolide), poly(L-lactide-co-D,L-lactide), poly(L-lactide-co-trimethylene carbonate);

the polysaccharide is selected from the group consisting of chitosan, levan, hyaluronic acid, heparin, dextran, and cellulose; and

the polyhydroxybutyric acid is selected from the group consisting of atactic, isotactic, syndiotactic, and a blend thereof.

7. The fiber strand according to claim 5, characterized in that the polymer is formed from at least one monomer selected from the group consisting of a lactide, a glycolide, a paradioxanone, a caprolactone, trimethylene carbonate, caprolactone, and a mixture thereof or a copolymer thereof.

8. The fiber strand according to claim 1, characterized in that the individual fibers (12) or at least parts of the fiber strand (10) are degradable or absorbable.

9. The fiber body according to claim 1, wherein the cords (30) forming the sheath (36) each comprises another core.

10. A fiber body for an implantable supporting body comprising at least two cords (30), wherein each cord (30) is formed from a plurality of fiber strands, wherein each fiber strand comprises at least two individual fibers (12), characterized in that the at least two individual fibers (12) are each shorter in their longitudinal extent than the longitudinal extent (14) of the fiber strand and their transverse extent is thinner than the transverse extent (16) of the fiber strand, further wherein the at least two cords (30) are embodied together to form a mechanically load-bearing structure comprising an implantable supporting body and a sheath (36), wherein,

one or more fiber strands (10) is arranged around a core (34);

or

a core (32) is formed from one or more fiber strands (10);

or

the sheath (36) is formed from a fiber strand material having at least one core (34) surrounded by a sheath (36).

11. The fiber body according to claim 10, characterized in that the fiber strands (10) are treated with a matrix material (22) and the matrix material (22) comprises at least one substance selected from the group consisting of a drug, a polymer, a drug-loaded polymer, and a drug-loaded biodegradable polymer.

12. The fiber body according to claim 11, characterized in that the polymer is formed from at least one monomer selected from the group consisting of a lactide, a glycolide, a paradioxanone, a caprolactone, trimethylene carbonate, caprolactone, and mixture or copolymer thereof.

13. A method for manufacturing an implantable supporting body (100) according to claim 12, characterized by

a) providing the cord (30) or fiber strand (10);

b) cutting the cord (30) or fiber strand (10) to size;

c) shaping the cord (30) and/or the fiber strand (10) after twisting, braiding or weaving the cord (30) or fiber strand (10) to form a final geometry; and

(d) impregnating the cord (30) and/or the fiber strand (10) with a matrix material (22).